… We found that patients diagnosed in the latest years showed a … survival of de novo mPCa
remains poor, with a median OS and CSS improvement of only 4 months in the latest years. …

… recent update of the SEER cohort showed a slightly increased survival in men with de novo
metastatic prostate … of all men with de novo metastatic prostate cancer in our study received …

… metastatic hormone-sensitive prostate cancer (mHSPC), docetaxel chemotherapy or abiraterone
may be added to ADT, with both agents conferring improved survival.… reaffirms previous …

… , increased survival in individuals with de novo metastatic castration-sensitive prostate cancer
(mCSPC), ie, metastatic … This may partly explain the survival improvement in the last study …

… during the last 30 years. … -2008 onward for prostate cancer, from 1999-2003 onward for
breast cancer, in … Other medicines that probably contributed to the improved survival in our study …

… In the last years, several prospective studies have focused on the treatment of … -volume
metastatic disease. After a median follow-up of 78.2 months, patients had better survival by the …

… In the past decade, a revolution in the treatment of metastatic … , resulting in an overall
reduction in tumour growth and improved survival 83 . Clinical studies across a wide range of …

… the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for
metastatic prostate … , we identified patients more than or equal to 18 years old with de novo …

… group demonstrated increased survival for patients receiving … Both 3-years OS and CSS
increased from the first to the last … However, prostate cancer patients with de novo metastases …

… metastatic prostate cancer patients; however, a subgroup analysis showed that RT improved
the survival in men with a low metastatic … Recent retrospective studies have used national …